| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/07/2002 | US6384049 Cancer treatment |
| 05/07/2002 | US6384045 Tricyclic and tetracyclic pyrones |
| 05/07/2002 | US6384027 Phthalocyanine analogs |
| 05/07/2002 | US6384019 Gemcitabine derivatives |
| 05/07/2002 | US6383808 Antisense inhibition of clusterin expression |
| 05/07/2002 | US6383793 Human osteoclast-derived cathepsin |
| 05/07/2002 | US6383790 Pyrazolo(3,4-d)pyrimidine based compound; anticarcinogenic agents; antitumor agents |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383760 Contacting receptor with test compound, then determining if compound binds to receptor |
| 05/07/2002 | US6383759 Non-invasive method to detect prostate cancer |
| 05/07/2002 | US6383739 Drug screening by isolating blood cells then cd8+ cells from donors, culturing with compound for 3 days, culturing in with interleukin-2, detecting immunodeficiency-virus suppressing lymphokine expression, then further analysis |
| 05/07/2002 | US6383733 Methods of screening for pharmacologically active compounds for the treatment of tumour diseases |
| 05/07/2002 | US6383494 Heat shock proteins |
| 05/07/2002 | US6383493 Methods and compositions for eliciting an immune response with hsp70-peptide complexes |
| 05/07/2002 | US6383492 Treatment of infectious diseases with gp96-peptide complexes |
| 05/07/2002 | US6383491 Prevention of infectious diseases with hsp90-peptide complexes |
| 05/07/2002 | US6383487 Antitumor |
| 05/07/2002 | US6383486 Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 05/07/2002 | US6383484 Antibodies to truncated VEGF-D and thereof |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2214503C Method for treating tumors |
| 05/07/2002 | CA2088760C Use of 2-phenyl-1,2-benzisoselanazol-3-(2h)-one |
| 05/06/2002 | WO2002038178A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |
| 05/06/2002 | CA2429404A1 Use of a compound antagonist of the esm-1 protein for producing a medicine for treating cancer |
| 05/03/2002 | WO2002035962A1 Hair clip |
| 05/03/2002 | CA2377219A1 Hair clip |
| 05/02/2002 | WO2002035242A1 Method for identifying novel molecules binding with lox receptor |
| 05/02/2002 | WO2002035236A1 Method for identifying novel molecules binding with the scavenger receptors and signalled via a toll receptor |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034915A2 Preferred segments of neural thread protein and methods of using the same |
| 05/02/2002 | WO2002034904A1 Novel g protein-coupled receptor protein and dna thereof |
| 05/02/2002 | WO2002034888A1 Ex vivo oxidatively stressed cll cells in chronic lymphocytic leukemia (cll) treatment |
| 05/02/2002 | WO2002034879A2 Method for introducing antisense oligonucleotides into eucaryotic cells |
| 05/02/2002 | WO2002034790A1 Variant igg3 rituxan r and therapeutic use thereof |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | WO2002034761A1 Pyranoside derivatives |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034748A1 Imidazopyridine derivatives |
| 05/02/2002 | WO2002034744A1 Quinazoline derivatives |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034727A2 Treatment of gastrointestinal stromal tumors |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034721A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/02/2002 | WO2002034717A1 Sulphur-containing indirubin derivatives, production and use thereof |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034708A2 Aliphatic amino-substituted demethoxylated hypocrellins and their synthesis |
| 05/02/2002 | WO2002034303A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/02/2002 | WO2002034300A1 Polymer based radionuclide containing particulate material |
| 05/02/2002 | WO2002034299A1 Inorganic low density radionuclide coated particles |
| 05/02/2002 | WO2002034298A1 Low density radionuclide-containing particulate material |
| 05/02/2002 | WO2002034293A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent |
| 05/02/2002 | WO2002034291A2 Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| 05/02/2002 | WO2002034289A1 Modulating angiogenesis |
| 05/02/2002 | WO2002034283A2 Vegh inhibitors and their use |
| 05/02/2002 | WO2002034282A2 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis |
| 05/02/2002 | WO2002034247A2 Anticancer agents based on regulation of protein prenylation |
| 05/02/2002 | WO2002034244A2 A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| 05/02/2002 | WO2002034239A1 Use of hydrophilic particles associated with antigens for preparing vaccine compositions |
| 05/02/2002 | WO2002034236A2 Lipid formulations for target delivery |
| 05/02/2002 | WO2002034205A2 Using heat shock proteins to increase immune response |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002034119A2 Vaccine immunotherapy for immune suppressed patients |
| 05/02/2002 | WO2002020525A3 Protein tyrosine phosphatase inhibitor |
| 05/02/2002 | WO2002014323A3 Polymorphs of an epothilone analog |
| 05/02/2002 | WO2002012537A3 Mutant trichosanthin |
| 05/02/2002 | WO2002002562A3 Heteropolycyclic inhibitors |
| 05/02/2002 | WO2002000827A3 A novel polypeptide, a dna-cysteine methyltransferase methylation protein 10 and the polynucleotide encoding the polypeptide |
| 05/02/2002 | WO2002000825A3 A novel polypeptide, a nuclear receptor protein stromal antigene 110.34 and the polynucleotide encoding the polypeptide |
| 05/02/2002 | WO2001098473A3 Method for isolating and purifying a protein and resulting protein |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001094529A3 A novel polypeptide, a human atp dependant serine proteinase 21 and the polynucleotide encoding the polypeptide |
| 05/02/2002 | WO2001091803A3 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 05/02/2002 | WO2001090332A3 Dna repair polypeptides and methods of use |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001074840A3 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregna 21-substituted 19-norpregnadienedione as antiprogestational agents |
| 05/02/2002 | WO2001072778A3 Method of identifying inhibitors of tie-2 |
| 05/02/2002 | WO2001070756A3 Lipopolysaccharides (lps) extracted from escherichia coli |
| 05/02/2002 | WO2001068708A3 Human and humanized fap-alpha-specific antibodies |
| 05/02/2002 | WO2001066772A3 Heparinase iii and uses thereof |
| 05/02/2002 | WO2001064749A3 Method for preparing anti-mif antibodies |
| 05/02/2002 | WO2001064741A3 Methods for selectively modulating survivin apoptosis pathways |
| 05/02/2002 | WO2001062931A3 ANTI-EGFRvIII SCFVS WITH IMPROVED CYTOTOXICITY AND YIELD, IMMUNOTOXINS BASED THEREON, AND METHODS OF USE THEREOF |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062289A3 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001060317A3 Kidney-specific tumor vaccine directed against kidney tumor antigen g-250 |
| 05/02/2002 | WO2001055393A3 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1 |
| 05/02/2002 | WO2001055210A3 Human cyr61 |
| 05/02/2002 | WO2001051635A3 Novel stra6 polypeptides |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001044264A3 Novel stromelysin inhibitors |
| 05/02/2002 | WO2001039762A3 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 05/02/2002 | WO2001034767A3 22 human secreted proteins |
| 05/02/2002 | WO2001023375A3 Substituted pyridines and pyridazines with angiogenesis inhibiting activity |